Jasper Therapeutics’ $103.5 Million Public Offering

Martina Bellini
Tagged:

Paul Hastings LLP advised Jasper Therapeutics on the deal.Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117)…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

…

This content is for Standard 1 Year members only.
Login Join Now